Patents by Inventor Claudia Beato

Claudia Beato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF
    Publication number: 20240109920
    Abstract: Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 4, 2024
    Inventors: Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Federico Sorana, Bruno Di Guglielmo, Chiara Padroni
  • Inhibitors of complement factors and uses thereof
    Patent number: 11814404
    Abstract: Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: November 14, 2023
    Assignees: ANNEXON, INC., APTUIT (VERONA) SRL
    Inventors: Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Federico Sorana, Bruno Di Guglielmo, Chiara Padroni
  • Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
    Patent number: 11773096
    Abstract: The present-disclosure relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof, which are capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the present disclosure can be used to treat p53-null cancer in a subject. In other embodiments, the compounds of the present disclosure can be used to treat metabolic disorders in a subject, including but not limited to type 2 diabetes and/or obesity.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: October 3, 2023
    Assignee: YALE UNIVERSITY
    Inventors: Ya Ha, Jonathan Ellman, Song Chen, Caroline Chandra Tjin, Fabrizio Micheli, Agostino Cianciulli, Claudia Beato
  • AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS
    Publication number: 20230250093
    Abstract: The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 10, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta ARMANI, Gabriele AMARI, Andrea RIZZI, Mafalda PAGANO, Luca RAVEGLIA, Claudia BEATO
  • INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20230148214
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: March 5, 2021
    Publication date: May 11, 2023
    Inventors: Albert W. Garofalo, Jacob Bradley Schwarz, Fabio Maria Sabbatini, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20230077268
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: May 11, 2022
    Publication date: March 9, 2023
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS
    Publication number: 20230063121
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 2, 2023
    Inventors: Gabriele AMARI, Elisabetta ARMANI, Mafalda PAGANO, Luca RAVEGLIA, Marta GIULIANI, Claudia BEATO
  • AROMATIC AMIDO DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS
    Publication number: 20230043672
    Abstract: The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are aromatic amido derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.
    Type: Application
    Filed: December 10, 2020
    Publication date: February 9, 2023
    Inventors: Gabriele AMARI, Elisabetta ARMANI, Mafalda PAGANO, Luca RAVEGLIA, Claudia BEATO
  • Indazoles and azaindazoles as LRRK2 inhibitors
    Patent number: 11427558
    Abstract: The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 30, 2022
    Assignee: ESCAPE Bio, Inc.
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Jacob Bradley Schwarz, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • INDAZOLES AS LRRK2 INHIBITORS
    Publication number: 20220162192
    Abstract: The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Inventors: Albert W. Garofalo, Stéphane De Lombaert, Daniele Andreotti, Fabio Maria Sabbatini, Elena Serra, Silvia Bernardi, Marco Migliore, Federica Budassi, Claudia Beato
  • INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF
    Publication number: 20220048930
    Abstract: Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
    Type: Application
    Filed: July 19, 2021
    Publication date: February 17, 2022
    Inventors: Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Frederico Sorana, Bruno Di Guglielmo, Chiara Padroni
  • Small-Molecule PI5P4K alpha/beta Inhibitors and Methods of Treatment Using Same
    Publication number: 20210292326
    Abstract: The present-disclosure relates to the discovery of novel 2-amino-dihydropteridinone compounds and analogues thereof, which are capable of inhibiting phosphatidylinositol phosphate kinases. In certain embodiments, the compounds of the present disclosure can be used to treat p53-null cancer in a subject. In other embodiments, the compounds of the present disclosure can be used to treat metabolic disorders in a subject, including but not limited to type 2 diabetes and/or obesity.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Inventors: Ya Ha, Jonathan Ellman, Song Chen, Caroline Chandra Tjin, Fabrizio Micheli, Agostino Cianciulli, Claudia Beato
  • FUSED TETRAZOLES AS LRRK2 INHIBITORS
    Publication number: 20210261553
    Abstract: The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 26, 2021
    Inventors: Albert W. Garofalo, Daniele Andreotti, Silvia Bernardi, Elena Serra, Marco Migliore, Fabio Maria Sabbatini, Claudia Beato, Paolo Vincetti, Federica Budassi